Date: 2016-05-27
Type of information: Licensing agreement
Compound: BET inhibitor program
Company: TG Therapeutics (USA - NY) Jubilant Biosys (India) Checkpoint Therapeutics (USA - NY)
Therapeutic area: Cancer - Oncology
Type agreement: development licensing
Action mechanism: BET inhibitor
Disease: hematological malignancies
Details: * On May 27, 2016, TG Therapeutics announced that as part of a broader agreement with Jubilant Biosys, an Indian biotechnology company, TG Therapeutics entered into a sub-license agreement with Checkpoint Therapeutics, a Fortress Biotech company, to develop and commercialize Jubilant's novel BET inhibitor program in the field of hematological malignancies. Checkpoint will develop and commercialize these small molecule inhibitors in solid tumors. The BET inhibitor program is the subject of an exclusive, worldwide license agreement pursuant to which Checkpoint in-licensed from Jubilant a family of patents covering compounds that inhibit BRD4, a member of the BET (Bromodomain and Extra Terminal) domain for cancer treatment.
Financial terms: Under the terms of the agreement, TG Therapeutics will pay an up-front licensing fee of $1 million and make additional payments contingent on certain preclinical, clinical, and regulatory milestones, including commercial milestones totaling up to approximately $177 million and a single-digit royalty on net sales. TG Therapeutics will also provide funding to support certain targeted research efforts at Jubilant Biosys.
Latest news:
